Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma
Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 369-378
DOI: 10.1080/14737167.2026.2634771 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 03.03.2026. Verfasst von Doris K Hansen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson & Johnson, Legend Biotech USA Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Global Real World Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
- PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, Waltham, MA, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- U.S Medical Affair, Legend Biotech USA Inc, USA.
- U.S Medical Affair, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
ORCID-Profile: Doris K Hansen, Omar Castaneda Puglianini, Saad Z Usmani, Sundar Jagannath
Förderung
- Johnson & Johnson
- Legend Biotech USA Inc
Zitieren
APA
Hansen, D. K., Lu, X., Castaneda Puglianini, O., Zhang, E., Usmani, S. Z., Sachdev, R., Perciavalle, M., De Wiest, D., Huo, S., Lee, S., Qureshi, Z. P., & Jagannath, S. (2026). Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 369-378. https://doi.org/10.1080/14737167.2026.2634771
Vancouver
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, et al. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):369-378. doi:10.1080/14737167.2026.2634771
BibTeX
@article{Hansen2026,
author = {Hansen, Doris K and Lu, Xiaoxiao and Castaneda Puglianini, Omar and Zhang, Eileen and Usmani, Saad Z and Sachdev, Rameet and Perciavalle, Matthew and De Wiest, Denise and Huo, Stephen and Lee, Seina and Qureshi, Zaina P and Jagannath, Sundar},
title = {Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {3},
pages = {369--378},
doi = {10.1080/14737167.2026.2634771}
}
EUVIMED